TABLE 1.
Panel of TCR Vβ monoclonal antibodies used in these studies and their expression in CD3+ CD8+ lymphocytes from healthy individuals
| Vβ antibody specificity or total | Fluorochrome | MAb clone | % Vβ expression in CD8+ TCRαβ+ cellsa
|
|
|---|---|---|---|---|
| Median | p10-p90 | |||
| Vβ 1 | PE and FITC | BL37.2 | 4.70 | 3.1-8.5 |
| Vβ 2 | PE and FITC | MPB2D5 | 5.60 | 3.3-8.7 |
| Vβ 3 | FITC | CH92 | 3.60 | 0.5-9.9 |
| Vβ 4 | PE and FITC | WJF24 | NA | |
| Vβ 5.1 | PE and FITC | IMMU157 | 3.50 | 1.6-7.3 |
| Vβ 5.2 | PE | 36213 | NA | |
| Vβ 5.3 | PE | 3D11 | NA | |
| Vβ 7.1 | PE and FITC | ZOE | 3.90 | 1.4-8.0 |
| Vβ 7.2 | FITC | ZIZOU4 | NA | |
| Vβ 8 | FITC | 56C5.2 | 4.60 | 2.6-7.0 |
| Vβ 9 | PE | FIN9 | 2.30 | 1.3-4.4 |
| Vβ 11 | PE | C21 | 0.50 | 0.5-1.1 |
| Vβ 12 | FITC | VER2.32 | 2.50 | 1.0-3.7 |
| Vβ 13.1 | PE | IMMU222 | NA | |
| Vβ 13.2 | PE | H132 | NA | |
| Vβ 13.6 | PE and FITC | JU74.3 | 1.90 | 0.8-3.6 |
| Vβ 14 | FITC | CAS1.1.3 | 4.80 | 1.7-13.4 |
| Vβ 16 | FITC | TAMAYA1.2 | 1.20 | 0.5-2.0 |
| Vβ 17 | PE and FITC | E17.5F3 | 5.00 | 2.5-7.0 |
| Vβ 18 | PE | BA62.6 | 0.50 | 0.5-0.9 |
| Vβ 20 | FITC | ELL1.4 | 1.80 | 0.5-5.1 |
| Vβ 21.3 | FITC | IG125 | 2.90 | 1.4-4.8 |
| Vβ 22 | PE and FITC | IMMU546 | 2.90 | 0.5-5.4 |
| Vβ 23 | PE | AF23 | 2.00 | 0.5-3.4 |
| Total | 54.20 | |||
a
Reference values (median) in healthy controls are derived from van den Beemd et al. (47). p10, 10th percentile; p90, 90th percentile; NA, not available.